FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]
From General Health Information to Specific Drug Risks
General health and science information has long served as a foundation for public understanding of medication risks and benefits. Within this broad domain, discussions of drug safety typically emphasize therapeutic efficacy and common side effects, while rare or delayed adverse events often receive less attention. The legacy of general health communication provides a framework for recognizing that all pharmaceuticals carry some degree of risk, yet the translation of this awareness into specific clinical contexts remains an ongoing challenge. This heritage naturally extends to the examination of bisphosphonate medications, a class widely prescribed for bone-related conditions. As public health discourse evolves, attention has shifted from general medication profiles to more focused inquiries about particular exposure scenarios. One such scenario involves the long-term use of Fosamax, a bisphosphonate, and its potential association with osteonecrosis of the jaw. This transition from broad health information to a specific drug-outcome concern reflects a growing need to understand how routine therapeutic exposure may, in certain populations, lead to uncommon but serious complications. The pivot here is not toward occupational settings but toward the clinical exposure context, where the patient's cumulative drug intake becomes the central variable in assessing risk.
Understanding Fosamax and Its Mechanism
Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The drug works by inhibiting bone resorption, thereby increasing bone mass and reducing fracture risk, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a serious adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation of ONJ typically involves pain, swelling, infection, and exposed bone in the mandible or maxilla. Diagnosis is based on clinical examination and imaging, often revealing areas of necrotic bone that fail to heal after dental procedures. The condition can lead to significant morbidity, including chronic pain, difficulty eating, and secondary infections.
Mechanistic Pathways and Risk Factors
The mechanistic pathways linking Fosamax to ONJ are not fully understood but are believed to involve the drug's potent inhibition of osteoclast activity. Bisphosphonates like Fosamax suppress bone turnover, which can impair the normal remodeling and repair processes in the jawbone. This is particularly relevant in the jaw, which undergoes high rates of bone turnover due to constant mechanical stress from chewing and the presence of teeth. The multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Additionally, bisphosphonates may have anti-angiogenic effects, reducing blood supply to the jawbone and contributing to tissue necrosis. The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuing the drug, but a subset may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
Causation Considerations and Warnings
Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under "Warnings and Precautions" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This section advises that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and that known risk factors include invasive dental procedures and concomitant therapies. It also notes that discontinuation of bisphosphonate treatment may reduce the risk for ONJ in patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the warning does not specify a precise timeline for risk or provide absolute risk estimates, which may leave some patients and clinicians unaware of the potential for harm, especially in long-term users. For affected patients, causation considerations are complex. While Fosamax is associated with ONJ, the condition can also occur spontaneously or due to other factors such as cancer, radiation therapy, or severe dental disease. The presence of known risk factors, such as tooth extraction or corticosteroid use, may confound the causal link. The timeline between exposure and documented harm can vary widely, from days to months after starting the drug, and the risk may increase with longer duration of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Patients who develop ONJ after starting Fosamax, especially without other clear risk factors, may have a stronger case for causation. However, the low incidence in clinical trials and the similarity to placebo rates suggest that individual susceptibility plays a role. In summary, Fosamax is a bisphosphonate that can cause osteonecrosis of the jaw, with mechanisms involving suppressed bone turnover and potential anti-angiogenic effects. The risk is increased by invasive dental procedures, longer exposure, and concomitant therapies. Warnings in the prescribing information address this risk but may not fully convey the variability in onset and individual risk. Patients and clinicians should weigh the benefits of Fosamax for osteoporosis prevention against the potential for ONJ, particularly in those with dental risk factors.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Community Resource & Benefit Desk
Request archival records or inquire about member-exclusive transition and benefit programs.
Frequently Asked Questions
What is Fosamax and how does it work?
Fosamax (alendronate sodium) is a bisphosphonate medication used to treat and prevent osteoporosis, increase bone mass in men with osteoporosis, treat glucocorticoid-induced osteoporosis, and treat Paget's disease of bone. It works by inhibiting bone resorption, thereby increasing bone mass and reducing fracture risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
What is osteonecrosis of the jaw (ONJ) and how is it linked to Fosamax?
Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, often associated with tooth extraction or local infection. Fosamax and other bisphosphonates can cause ONJ by suppressing bone turnover and potentially reducing blood supply to the jawbone. The risk increases with longer exposure and invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
What are the risk factors for developing ONJ while taking Fosamax?
Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and pre-existing dental disease. The risk may also increase with longer duration of Fosamax use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
How is ONJ diagnosed and what are its symptoms?
ONJ is diagnosed through clinical examination and imaging, revealing necrotic bone that fails to heal after dental procedures. Symptoms include pain, swelling, infection, and exposed bone in the jaw, which can lead to chronic pain, difficulty eating, and secondary infections.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Free and confidential. No obligation — an initial records screening only.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.